Sign In
NASDAQ:DBVT
DBV Technologies S.A. Stock News
$8.53
-0.370 (-4.16%)
At Close: Apr 25, 2025
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
04:30pm, Friday, 11'th Apr 2025
Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – N
3 Biopharmaceutical Stocks Bucking the Sell-Off
07:02am, Thursday, 10'th Apr 2025
With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be
DBV Technologies ADRs Rise After Up to $306.9M in New Financing
11:09am, Friday, 28'th Mar 2025
American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million.
Châtillon, France, March 27, 2025 DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission an
Châtillon, France, March 24, 2025 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin® Peanut Patch in 4 – 7-year-olds,
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
04:01pm, Tuesday, 25'th Feb 2025
Châtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clin
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
04:05pm, Monday, 13'th Jan 2025
AMF Regulated Information Châtillon, France, January 13, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasd
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids
09:59am, Thursday, 12'th Dec 2024
On Wednesday, DBV Technologies SA DBVT reached a significant milestone with the FDA regarding its Viaskin Peanut patch for toddlers aged 1–3 years.
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
04:05pm, Wednesday, 11'th Dec 2024
Châtillon, France, December 11th, 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key stu
DBV Technologies Announces Plan to Implement ADS Ratio Change
04:30pm, Monday, 11'th Nov 2024
Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J
DBV Technologies Reports Third Quarter 2024 Financial Results
04:30pm, Wednesday, 06'th Nov 2024
Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (E
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe
04:45pm, Tuesday, 22'nd Oct 2024
Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
04:30pm, Friday, 18'th Oct 2024
Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-s
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
04:30pm, Monday, 23'rd Sep 2024
Châtillon, France, September 23, 2024 DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial In Q3 2024, DBV exceeded its recruitment goal and successfully closed the screening p
DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
04:30pm, Wednesday, 04'th Sep 2024
Châtillon, France, September 4, 2024 DBV Technologies to Participate in the H.C. Wainwright 26 th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq
